A nomogram to predict the probability of axillary lymph node metastasis in early breast cancer patients with positive axillary ultrasound

Citations Over TimeTop 10% of 2016 papers

Abstract

Among patients with a preoperative positive axillary ultrasound, around 40% of them are pathologically proved to be free from axillary lymph node (ALN) metastasis. We aimed to develop and validate a model to predict the probability of ALN metastasis as a preoperative tool to support clinical decision-making. Clinicopathological features of 322 early breast cancer patients with positive axillary ultrasound findings were analyzed. Multivariate logistic regression analysis was performed to identify independent predictors of ALN metastasis. A model was created from the logistic regression analysis, comprising lymph node transverse diameter, cortex thickness, hilum status, clinical tumour size, histological grade and estrogen receptor, and it was subsequently validated in another 234 patients. Coefficient of determination (R(2)) and the area under the ROC curve (AUC) were calculated to be 0.9375 and 0.864, showing good calibration and discrimination of the model, respectively. The false-negative rates of the model were 0% and 5.3% for the predicted probability cut-off points of 7.1% and 13.8%, respectively. This means that omission of axillary surgery may be safe for patients with a predictive probability of less than 13.8%. After further validation in clinical practice, this model may support increasingly limited surgical approaches to the axilla in breast cancer.

Related Papers

• Ultrasonographic detection of metastatic axillary lymph nodes in breast cancer.(1990)
• → AXILLARY NODES IN BREAST CANCER(1972)58 cited
• → Exploring innovative nodal imaging and treatment strategies in breast cancer : a next step in patient tailored axillart treatment?(2015)
• → AB023. 11. Axillary complete pathological response to neo-adjuvant chemotherapy in breast cancer, can we predict it?(2019)
• → The Benefit of Routine Axillary Sonographic Assessment in cN0 Breast Cancer Patients(2022)